Cargando…

Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial

BACKGROUND: In practice, the optimal dose of alfentanil that should be used when painless bronchoscopy is performed is unknown. The purpose of this study was to investigate the effective dose of alfentanil in suppressing bronchoscopy responses to painless bronchoscopy with an i-gel supraglottic airw...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Nanjin, Wang, Xiaodan, Chen, Lingyang, Wang, Mingcang, Jiang, Yongpo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186247/
https://www.ncbi.nlm.nih.gov/pubmed/35693612
http://dx.doi.org/10.21037/jtd-22-412
_version_ 1784724890130055168
author Chen, Nanjin
Wang, Xiaodan
Chen, Lingyang
Wang, Mingcang
Jiang, Yongpo
author_facet Chen, Nanjin
Wang, Xiaodan
Chen, Lingyang
Wang, Mingcang
Jiang, Yongpo
author_sort Chen, Nanjin
collection PubMed
description BACKGROUND: In practice, the optimal dose of alfentanil that should be used when painless bronchoscopy is performed is unknown. The purpose of this study was to investigate the effective dose of alfentanil in suppressing bronchoscopy responses to painless bronchoscopy with an i-gel supraglottic airway device. METHODS: Patients aged 18–70 years, with American Society of Anesthesiologists (ASA) physical status I–II, who planned to undergo painless bronchoscopy were recruited for this study. Alfentanil was administered intravenously 2 minutes before propofol administration. The response to bronchoscopy was measured, including oxygen saturation (SPO(2)) and changes in respiratory rhythm. The median effective dose of alfentanil (ED(50)) required to alleviate responses to the bronchoscopy was calculated using Dixon’s up-and-down method in the female and male groups. Probit analysis was used to generate a dose-response curve in each group. RESULTS: A total of 48 patients were recruited for the study including 25 females and 23 males. The ED(50) of alfentanil for suppressing responses to painless bronchoscopy in females and males was 13.68±4.75 and 17.96±3.45 µg/kg, respectively. The difference was not statistically significant between the two groups (P=0.078). Probit analysis showed the ED(50) of alfentanil in female bronchoscopy was 12.4 µg/kg [95% confidence interval (CI): 4.5 to 17 µg/kg]. In men, the ED(50) of alfentanil was 16.4 µg/kg (95% CI: 12.1 to 20.1 µg/kg). According to the probit analysis, the 95% effective dose (ED(95)) of alfentanil was 22.4 µg/kg (95% CI: 17.5 to 67.3 µg/kg) in female bronchoscopy. In men, the ED(95) of alfentanil was 23.3 µg/kg (95% CI: 19.8 to 46.2 µg/kg). CONCLUSIONS: Our data suggest that there were no obvious differences between men and women in the effective dose of alfentanil in painless bronchoscopy.
format Online
Article
Text
id pubmed-9186247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-91862472022-06-11 Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial Chen, Nanjin Wang, Xiaodan Chen, Lingyang Wang, Mingcang Jiang, Yongpo J Thorac Dis Original Article BACKGROUND: In practice, the optimal dose of alfentanil that should be used when painless bronchoscopy is performed is unknown. The purpose of this study was to investigate the effective dose of alfentanil in suppressing bronchoscopy responses to painless bronchoscopy with an i-gel supraglottic airway device. METHODS: Patients aged 18–70 years, with American Society of Anesthesiologists (ASA) physical status I–II, who planned to undergo painless bronchoscopy were recruited for this study. Alfentanil was administered intravenously 2 minutes before propofol administration. The response to bronchoscopy was measured, including oxygen saturation (SPO(2)) and changes in respiratory rhythm. The median effective dose of alfentanil (ED(50)) required to alleviate responses to the bronchoscopy was calculated using Dixon’s up-and-down method in the female and male groups. Probit analysis was used to generate a dose-response curve in each group. RESULTS: A total of 48 patients were recruited for the study including 25 females and 23 males. The ED(50) of alfentanil for suppressing responses to painless bronchoscopy in females and males was 13.68±4.75 and 17.96±3.45 µg/kg, respectively. The difference was not statistically significant between the two groups (P=0.078). Probit analysis showed the ED(50) of alfentanil in female bronchoscopy was 12.4 µg/kg [95% confidence interval (CI): 4.5 to 17 µg/kg]. In men, the ED(50) of alfentanil was 16.4 µg/kg (95% CI: 12.1 to 20.1 µg/kg). According to the probit analysis, the 95% effective dose (ED(95)) of alfentanil was 22.4 µg/kg (95% CI: 17.5 to 67.3 µg/kg) in female bronchoscopy. In men, the ED(95) of alfentanil was 23.3 µg/kg (95% CI: 19.8 to 46.2 µg/kg). CONCLUSIONS: Our data suggest that there were no obvious differences between men and women in the effective dose of alfentanil in painless bronchoscopy. AME Publishing Company 2022-05 /pmc/articles/PMC9186247/ /pubmed/35693612 http://dx.doi.org/10.21037/jtd-22-412 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Chen, Nanjin
Wang, Xiaodan
Chen, Lingyang
Wang, Mingcang
Jiang, Yongpo
Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial
title Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial
title_full Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial
title_fullStr Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial
title_full_unstemmed Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial
title_short Estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an Up-and-Down Sequential Allocation Trial
title_sort estimation of the median effective dose and the 95% effective dose of alfentanil required to inhibit the bronchoscopy reaction during painless bronchoscopy with i-gel supraglottic airway device: an up-and-down sequential allocation trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186247/
https://www.ncbi.nlm.nih.gov/pubmed/35693612
http://dx.doi.org/10.21037/jtd-22-412
work_keys_str_mv AT chennanjin estimationofthemedianeffectivedoseandthe95effectivedoseofalfentanilrequiredtoinhibitthebronchoscopyreactionduringpainlessbronchoscopywithigelsupraglotticairwaydeviceanupanddownsequentialallocationtrial
AT wangxiaodan estimationofthemedianeffectivedoseandthe95effectivedoseofalfentanilrequiredtoinhibitthebronchoscopyreactionduringpainlessbronchoscopywithigelsupraglotticairwaydeviceanupanddownsequentialallocationtrial
AT chenlingyang estimationofthemedianeffectivedoseandthe95effectivedoseofalfentanilrequiredtoinhibitthebronchoscopyreactionduringpainlessbronchoscopywithigelsupraglotticairwaydeviceanupanddownsequentialallocationtrial
AT wangmingcang estimationofthemedianeffectivedoseandthe95effectivedoseofalfentanilrequiredtoinhibitthebronchoscopyreactionduringpainlessbronchoscopywithigelsupraglotticairwaydeviceanupanddownsequentialallocationtrial
AT jiangyongpo estimationofthemedianeffectivedoseandthe95effectivedoseofalfentanilrequiredtoinhibitthebronchoscopyreactionduringpainlessbronchoscopywithigelsupraglotticairwaydeviceanupanddownsequentialallocationtrial